Table 1 |
|||
|
Patient, disease and treatment characteristics |
|||
|
Characteristic |
US (N = 68) |
EU (N = 47) |
|
|
|
|||
|
Age in years, mean ± SD (range) |
40.9 ± 16.2 (19-83) |
37.9 ± 16.5 (18-74) |
|
|
Female gender, N (%) |
33 (48.5) |
18 (38.3) |
|
|
Race, N (%) |
Caucasian/white |
54 (79.4) |
46 (97.9) |
|
Black |
10 (14.7) |
0 (0.0) |
|
|
Other |
4 (5.9) |
1 (2.1) |
|
|
BSA at baseline in m2, mean ± SD (range) |
1.94 ± 0.26 (1.42-2.53) |
1.85 ± 0.21 (1.41-2.28) |
|
|
ECOG status, N (%) |
0 |
47 (69.1) |
30 (63.8) |
|
1 |
20 (29.4) |
14 (29.8) |
|
|
2 |
1 (1.5) |
3 (6.4) |
|
|
Disease stage 1, N (%) |
I |
8 (12.1) 2 |
5 (10.6) |
|
II |
30 (45.5) 2 |
28 (59.6) |
|
|
III |
23 (34.8) 2 |
8 (17.0) |
|
|
IV |
5 (7.6) 2 |
6 (12.8) |
|
|
Prior radiotherapy, N (%) |
6 (8.8) |
0 (0.0) |
|
|
Baseline WBC in 103/mm3, mean ± SD; median |
9.4 ± 4.9; 7.8 |
9.5 ± 3.8; 8.4 |
|
|
Baseline ANC in 103/mm3, mean ± SD; median |
6.5 ± 3.3; 5.3 2 |
7.2 ± 3.6; 6.6 |
|
|
Diabetes, N (%) |
8 (11.8) |
0 (0.0) |
|
|
Cardiac comorbidity, N (%) |
0 (0.0) |
2 (4.3) |
|
|
Planned dose intensity in mg/m2/week, mean ± SD; median |
|||
|
Bleomycin |
4.9 ± 0.9; 4.9 |
5.3 ± 1.2; 5.0 |
|
|
Doxorubicin |
12.5 ± 1.9; 12.3 |
12.8 ± 2.7; 12.43 |
|
|
Dacarbazine |
184.0 ± 29.5; 183.6 |
198.3 ± 50.2; 186.7 |
|
|
Vinblastine |
3.0 ± 0.5; 2.9 |
3.2 ± 0.8; 3.0 |
|
|
Planned cycle number, N (%) |
≤ 3 |
0 (0.0) |
2 (4.3) |
|
4-5 |
29 (42.6) |
16 (34.0) |
|
|
6 |
38 (55.9) |
26 (55.3) |
|
|
≥ 8 |
1 (1.5) |
3 (6.4) |
|
|
Planned cycle length in days, N (%) |
14 |
7 (10.3) |
5 (10.6) |
|
21 |
5 (7.4) |
2 (4.3) |
|
|
28 |
56 (82.4) |
40 (85.1) |
|
|
|
|||
|
BSA body surface area; ECOG Eastern Cooperative Oncology Group; WBC white blood cell count; ANC absolute neutrophil count. 1 US: based on American Joint Committee Cancer staging; EU: based on Ann Arbor staging. 2 N = 66 due to missing values. 3N = 44 as 3 EU patients received epirubicin. |
|||
|
Schwenkglenks et al. Journal of Hematology & Oncology 2010 3:27 doi:10.1186/1756-8722-3-27 |
|||
